The Existing Drug Nifuroxazide as an Antischistosomal Agent: <i>In Vitro</i> , <i>In Vivo</i> , and <i>In Silico</i> Studies of Macromolecular Targets
Vinícius Roquini, Ana C. Mengarda, Rayssa A. Cajás, Milene F. Martins-da-Silva, Julia Godoy-Silva, Gustavo Aparecido dos Santos, Maria Cristina Carvalho do Espírito Santo, Thais Fernanda Amorim Pavani, Vanusa A. Melo, M. C. Salvadori, F. S. Teixeira, Daniela Rando, Josué de Moraes
Abstract
The increasing recognition of the burden imposed by helminthiasis, associated with the limited therapeutic arsenal, has led to initiatives and strategies to research and develop new drugs for the treatment of schistosomiasis. One of these strategies is drug repurposing, which considers low-risk compounds with potentially reduced costs and shorter time for development.
Topics & Concepts
In silicoIn vivoDrugPharmacologyNeglected tropical diseasesRepurposingDrug repositioningDrug discoveryMedicineComputational biologyChemistryBioinformaticsBiologyBiotechnologyInternal medicineBiochemistryGeneDiseaseEcologyParasites and Host InteractionsResearch on Leishmaniasis StudiesHelminth infection and control